WO2026032185 - PHARMACEUTICAL COMPOSITION
National phase entry is expected:
Publication Number
WO/2026/032185
Publication Date
12.02.2026
International Application No.
PCT/CN2025/112343
International Filing Date
04.08.2025
Title **
[English]
PHARMACEUTICAL COMPOSITION
[French]
COMPOSITION PHARMACEUTIQUE
[Chinese]
药物组合物
Applicants **
ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD.
Inventors
REN, Tiantian
TONG, Xidi
Priority Data
202411080815.5
08.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1630 | |
| EPO | Filing, Examination, Granting | 11565 | |
| Japan | Filing, Examination, Granting | 2078 | |
| South Korea | Filing, Examination, Granting | 1913 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,926
Contact Us
Abstract[English]
The present invention provides a pharmaceutical composition comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, a hydrate thereof, a tautomer thereof, or a stereoisomer thereof, wherein the pharmaceutical composition has a pH of no greater than 12.[French]
La présente invention concerne une composition pharmaceutique comprenant un composé représenté par la formule (I) ou un sel pharmaceutiquement acceptable de celui-ci, un promédicament de celui-ci, un solvate de celui-ci, un hydrate de celui-ci, un tautomère de celui-ci, ou un stéréoisomère de celui-ci, la composition pharmaceutique ayant un pH inférieur ou égal à 12.[Chinese]
本发明提供一种药物组合物，包括式(I)所示的化合物或其药学上可接受的盐、前体药物、溶剂合物、水合物、互变异构体、或立体异构体，所述药物组合物的pH不超过12；